What MIMS does

MIMS is a UK life science publishing business, founded in 1959 and owned by Haymarket Media Group Ltd., that produces the essential online prescribing and clinical reference for UK general practice. The core product is a pharmacist-compiled database of more than 3,000 hand-crafted drug summaries updated continuously throughout each working day, browsable by disease and by 500+ manufacturers, supplemented by drug comparison tables, eight live trackers (covering shortages, new/deleted products, generics, price changes, indications, products coming soon, and NICE technology appraisals), quick-reference NICE guideline summaries, visual guides for diabetes and respiratory devices, and 16 therapy-area resource centres (MIMS Clinics). The platform is grounded in official Summary of Product Characteristics and NICE guidance and is explicitly independent of pharmaceutical marketing influence. A separate Inhaler Carbon Emissions Table, developed with RightBreathe and the Primary Care Respiratory Society, supports greener inhaler prescribing and has been named a recommended resource by Pharmacy Declares.

MIMS monetises through three primary streams: individual annual subscriptions booked online (with a 30-day free trial and a freemium tier offering limited article access plus free bulletins), quote-based corporate and multi-user subscriptions sold by a dedicated account director into NHS Trusts, Primary Care Networks, Integrated Care Boards, and pharmaceutical companies, and a pharmaceutical advertising and sponsorship business that includes banners, overlays, sponsored MIMS clinics, sponsored drug comparison tables, and the MIMS Connect sponsored content programme. The product is distributed within the broader MIMS Healthcare Network, which bundles MIMS Learning (over 500 CPD learning activities plus a CPD organiser), MIMS Learning Live (webinars and in-person conferences), MIMS Pharma (market insights and trackers for the pharmaceutical industry), GPonline, and GP Business. Operations are UK-only, headquartered in Twickenham, with 51-100 employees, and print publication was discontinued in 2024 in favour of an online-only model. The platform serves UK GPs, pharmacists, NHS institutional buyers, and pharmaceutical companies seeking HCP-targeted commercial channels.

Name

MIMS

Legal name

Haymarket Media Group Ltd.

Website

https://mims.co.uk

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

51–100 employees

Short description

MIMS is a UK life science publishing business, founded in 1959 and owned by Haymarket Media Group, that operates a pharmacist-compiled online prescribing and clinical reference database of 3,000+ drug summaries for UK GPs, pharmacists, NHS organisations, and pharmaceutical advertisers.

Ownership category

akta.pro rank

Product category

Drug Information and Clinical Reference Publishing

NAICS

Web Search Portals, Libraries, Archives, and Other Information Services (5192)

SIC

Periodicals: Publishing Or Publishing & Printing (2721)

akta.pro primary industry

Medical Information Services (MI Contact Centers) (HLAGALAE)

Keywords

• Drug prescribing reference
• Clinical decision support
• Pharmaceutical information services
• Medical reference publishing
• Continuing professional development

Headquarters

HQ city

Twickenham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Annual Subscriptions: Individual healthcare professionals pay annual subscription for full access to MIMS online database, drug comparison tables, shortage trackers, and guideline summaries.
2. Corporate/Multi-user Subscriptions: Team and company-wide subscriptions tailored to business needs, sold through dedicated account director for NHS Trusts, PCNs, ICBs, and pharmaceutical companies.
3. Advertising and Sponsorship: Pharmaceutical companies advertise alongside specific disease areas. Creative solutions include banners, overlays, sponsored MIMS clinics, and sponsored drug comparison tables. MIMS Connect articles are funded by commercial partners.
4. Free Trial Conversion: 30-day free trial drives conversion to paid annual subscriptions.
5. Bulletin Services: Four bulletins available: MIMS Prescribing Update (3x weekly), MIMS Drug Shortages Update (weekly, subscribers only), MIMS Clinics (regular round-ups), MIMS Alert (safety alerts as they happen).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

MIMS publishes and maintains an online drug information database and clinical reference for UK healthcare professionals, featuring 3,000+ drug summaries compiled by pharmacists, live trackers for shortages and new products, comparison tables, clinical guidelines, and CPD resources. Since 2024, the service is delivered exclusively through an online subscription platform.

Product overview

MIMS is a comprehensive online prescribing and clinical reference platform for UK general practice, offering a portfolio of interconnected products and services. The core offering is the MIMS Online Database containing 3,000+ drug summaries updated daily, supplemented by MIMS Tables (drug comparison charts), MIMS Trackers (live supply and product status updates), MIMS Guidelines (NICE guidance summaries), MIMS Visual Guides (device tutorials), and MIMS Clinics (therapeutic area resource centres). The MIMS Healthcare Network ecosystem extends to MIMS Learning (500+ CPD activities), MIMS Learning Live (events), MIMS Pharma (pharma industry intelligence), GPonline, and GP Business. All content is compiled by pharmacists based on official SPCs and is provided via subscription.

Differentiator

Problem solved

Functional benefit

Products and services

• MIMS Online Drug Information Database Subscription-based online database of 3,000+ drug summaries compiled by pharmacists, with live trackers for shortages and new products, drug comparison tables, and clinical guidelines for UK healthcare professionals.
• MIMS Bulletins Email bulletin service providing MIMS subscribers with curated drug news, regulatory alerts, and clinical updates.
• MIMS Learning Online continuing professional development (CPD) platform providing modules and resources for UK GPs and primary care clinicians.
• MIMS Learning Live Live educational events and conferences for GPs and primary care clinicians, complementing the online MIMS Learning CPD offering.
• MIMS Pharma Market intelligence and insight service providing pharmaceutical companies with UK prescribing and market intelligence to support commercial strategy.
• GPonline News, analysis, and clinical content publication serving UK GPs and the wider primary care community.
• GP Business Business and operational resource providing news, guidance, and tools for UK GP practice management and primary care business operations.

Quantifiable outcome

• Updated throughout each working day with changes to drug information and prescribing news
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Five partnerships are on record, tiered core and minor.

• RightBreathecoreTechnology or IntegrationRightBreathe experts collaborated with MIMS to develop the comprehensive table of inhaler carbon emissions, providing detailed carbon emissions data and at-a-glance carbon footprint ratings for inhalers available in the UK.
• Primary Care Respiratory SocietycoreStrategic or Co-development PartnerPCR Society experts consulted on the inhaler carbon emissions table development. MIMS inhaler carbon emissions table is listed among resources recommended by PCRS.
• Pharmacy DeclaresminorStrategic or Co-development PartnerMIMS inhaler carbon emissions table is listed among resources recommended by Pharmacy Declares.
• ViatrisminorGTM or Marketing PartnerSponsor of MIMS Connect article on alternative to daily antibiotic prophylaxis recommended by NICE for recurrent UTI.
• Aspire Pharma LtdminorGTM or Marketing PartnerSponsor of MIMS Connect article on tailored management of acute otitis externa.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Epocrates: Epocrates is a widely-used point-of-care drug reference and clinical tool for physicians and pharmacists. It competes with MIMS in providing on-demand drug information, interaction checks, and prescribing guidance to frontline prescribers.
• Medscape: Medscape is a clinical reference and drug information platform serving physicians globally with free drug reference tools plus sponsored content. It competes with MIMS on drug information access and pharma-sponsored physician engagement, though with a broader global focus.
• Lexicomp: Lexicomp is Wolters Kluwer's clinical drug reference solution providing point-of-care drug information to physicians, pharmacists, and nurses. It competes with MIMS on hospital and enterprise drug reference subscriptions and is sold into similar institutional healthcare budgets globally.
• DynaMed: DynaMed is EBSCO's evidence-based clinical decision support tool used by physicians including UK GPs. It overlaps with MIMS in providing clinician-facing reference content sold via individual and enterprise subscriptions to healthcare organizations.
• BMJ Best Practice: BMJ Best Practice is a clinical decision support tool widely used by UK GPs and other clinicians as a subscription reference service. It directly competes with MIMS for HCP subscription budgets and physician mindshare in UK general practice prescribing and clinical decision workflows.
• UpToDate: UpToDate is Wolters Kluwer's evidence-based clinical decision support resource used by clinicians worldwide on subscription. It overlaps with MIMS in clinical reference for GPs, competing for individual clinician subscriptions and enterprise licenses at NHS Trusts and similar institutions.
• ClinicalKey: ClinicalKey is Elsevier's clinical reference platform aggregating medical books, journals, drug information, and clinical decision support. It competes with MIMS for institutional healthcare subscriptions and provides overlapping drug reference content to UK clinicians.
• British National Formulary (BNF): The BNF is the UK's authoritative drug reference publication, provided free to NHS users via NICE. It directly competes with MIMS in drug information and prescribing guidance for UK HCPs, and is MIMS's primary free-alternative competitor that pressures subscription value perception.

Others

• Royal Pharmaceutical Society: The Royal Pharmaceutical Society publishes the British National Formulary (BNF) and maintains professional standards for pharmacists. It is the principal publishing competitor to MIMS in UK prescribing reference and represents the dominant free alternative that pressures MIMS's subscription economics.

Broad incumbents

• NICE: NICE is a UK governmental body that produces free clinical guidelines, technology appraisals, and hosts the BNF. While not a subscription product, NICE's free guidance competes structurally with MIMS's paid subscription value proposition across UK primary care prescribing decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mims
• Facebookfacebook.com/mimsonline
• Xx.com/mimsonline

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIMS